SNS Insider Reports: Retinal Surgery market to Grow at 6.05% CAGR, Fueled by Minimally Invasive Tools, Aging Population & Increasing diabetic Retinopathy Cases ...
Weight-loss drugs such as semaglutides or tirzepatides may raise patients’ risk of nonarteritic anterior ischemic optic ...
Blurry vision at night: It can be a symptom of diabetes retinopathy, a condition where high blood sugar damages eye blood vessels and nerves, causing distorted or decreased vision.
Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...
Can supplementing with vitamins and minerals protect your eye health? Learn more about the role of nutrients in age-related ...
Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...
3d
GlobalData on MSNRegeneron’s macular oedema therapy shows promise in Phase III trialIn the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.
The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...
Google and Perceptra, a Google technology licensing partner, are joining forces to provide AI-powered diabetic-retinopathy (DR) screening to around 1 million people in underserved communities across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results